WILSON TROY EDWARD 4
4 · Avidity Biosciences, Inc. · Filed Aug 8, 2025
Insider Transaction Report
Form 4
WILSON TROY EDWARD
Director
Transactions
- Sale
Common Stock
2025-08-06$45.00/sh−22,000$990,000→ 69,425 total - Sale
Common Stock
2025-08-06$45.00/sh−15,000$675,000→ 285,000 total(indirect: By Trust) - Exercise/Conversion
Common Stock
2025-08-06$12.48/sh+7,500$93,600→ 76,925 total - Sale
Common Stock
2025-08-06$45.00/sh−17,777$799,965→ 17,776 total(indirect: By Trust) - Sale
Common Stock
2025-08-06$45.00/sh−15,000$675,000→ 285,000 total(indirect: By Trust) - Sale
Common Stock
2025-08-06$45.00/sh−17,777$799,965→ 17,776 total(indirect: By Trust) - Exercise/Conversion
Stock Option (Right to Buy)
2025-08-06−22,000→ 0 totalExercise: $12.03Exp: 2032-06-14→ Common Stock (22,000 underlying) - Exercise/Conversion
Common Stock
2025-08-06$12.03/sh+22,000$264,660→ 91,425 total - Sale
Common Stock
2025-08-06$45.00/sh−7,500$337,500→ 69,425 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-08-06−7,500→ 14,500 totalExercise: $12.48Exp: 2033-06-14→ Common Stock (7,500 underlying)
Holdings
- 13,711(indirect: By Trust)
Common Stock
- 11,851(indirect: By Trust)
Common Stock
- 11,851(indirect: By Trust)
Common Stock
Footnotes (2)
- [F1]All exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on December 4, 2024.
- [F2]All shares of common stock subject to this option were fully vested and exercisable as of the date of execution of this option by Reporting Person.